Online citations, reference lists, and bibliographies.

Neoadjuvant And Intrapleural Therapies For Malignant Pleural Mesothelioma.

A. Tsao, R. Mehran, J. Roth
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Historically, malignant pleural mesothelioma patients with potentially resectable disease have been treated with surgery and radiation alone. With improvements in systemic and intrapleural treatment options, a movement toward multi-modality therapy has become more common. Systemic treatment options largely consist of neoadjuvant chemotherapy with platinum doublets and most recently novel targeted agents, such as dasatinib. Intrapleural strategies have included injecting chemotherapy, chemotherapy with hyper thermic per fusion, gene therapy, and immunotherapy. The following review discusses the latest results in neoadjuvant and intrapleural therapies in malignant pleural mesothelioma.
This paper references
10.1378/chest.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1016/0003-4975(94)91066-9
Aggressive multimodality therapy for malignant pleural mesothelioma.
T. Rice (1994)
10.1200/JCO.2008.26.15_SUPPL.7604
Lung-sparing intrapleural chemotherapy plus P32 radiation for pleural mesothelioma
R. Taub (2008)
10.1200/jco.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1002/1097-0142(20011015)92:8<2197::AID-CNCR1563>3.0.CO;2-F
Hyperthermic pleural perfusion with cisplatin
A. Yellin (2001)
10.1177/030089169608200111
Surgery Followed by Intracavitary plus Systemic Chemotherapy in Malignant Pleural Mesothelioma
M. Colleoni (1996)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1089/HUM.1998.9.14-2121
Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.
K. Molnar-Kimber (1998)
10.1378/CHEST.120.4.1167
Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
H. Schouwink (2001)
10.1200/JCO.2007.25.18_SUPPL.7561
A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM)
L. Krug (2007)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1038/bjc.1995.501
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
S. H. Goey (1995)
10.1089/HUM.1998.9.7-1083
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
D. Sterman (1998)
10.1159/000227208
A new device for the treatment of pleural malignancies: intrapleural chemohyperthermia preliminary report.
P. Y. Carry (1993)
10.1016/J.IJROBP.2005.03.041
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
V. Gupta (2005)
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1016/J.BRACHY.2004.11.003
A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma.
K. Rosenzweig (2005)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1158/1078-0432.CCR-05-0405
Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy
D. Sterman (2005)
Health effects among world trade center respond
SM Levin (2005)
10.1158/1535-7163.MCT-07-0052
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
A. Tsao (2007)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1053/SONC.2002.30230
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/S0169-5002(07)70112-5
36 Health effects among World Trade Center responders
S. Levin (2006)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.1158/1078-0432.CCR-07-0403
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
D. Sterman (2007)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1245/ASO.2003.03.022
Cytoreductive Surgery Combined With Intraoperative Hyperthermic Intrathoracic Chemotherapy for Stage I Malignant Pleural Mesothelioma
S. van Ruth (2003)
10.1016/j.hoc.2005.09.004
Gene therapy for malignant pleural mesothelioma.
D. Sterman (1998)
10.3816/CLC.2004.N.008
Integration of multimodality approaches in the management of malignant pleural mesothelioma.
Derlis Martino (2004)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1016/J.EJCTS.2006.11.046
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
M. Lucchi (2007)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1038/sj.bjc.6601957
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
10.1002/1097-0142(19910415)67:8<2033::AID-CNCR2820670804>3.0.CO;2-8
Activity of intrapleural recombinant gamma‐interferon in malignant mesothelioma
C. Boutin (1991)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3
Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma
P. Astoul (1998)
10.1016/S0140-6736(04)17108-0
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1016/S1547-4127(04)00109-4
Innovative therapies: intraoperative intracavitary chemotherapy.
M. Chang (2004)
10.1200/JCO.2005.00.802
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
C. Lu (2005)
10.1378/chest.106.6_Supplement.359S
Trials in malignant mesothelioma. LCSG 851 and 882.
V. Rusch (1994)
10.1002/jso.2930600410
Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience.
J. D. Lee (1995)
10.1016/S0022-5223(99)70297-7
Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.
G. Ratto (1999)
Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
V. Rusch (1997)
10.1016/J.THORSURG.2004.06.001
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications.
M. Chang (2004)



This paper is referenced by
10.3810/pgm.2012.05.2555
Asbestos–Related Pleuropulmonary Diseases: Benign and Malignant
A. Lazarus (2012)
10.1016/j.athoracsur.2014.12.077
Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?
C. Munck (2015)
10.1007/s12094-011-0699-5
SEOM guidelines for the treatment of malignant pleural mesothelioma
P. Lianes (2011)
10.1007/978-3-642-10862-4_8
Chemotherapy and radiotherapy for mesothelioma.
Xavier Dhalluin (2011)
10.3892/ijo.2018.4555
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma
Tatsuya Kato (2018)
10.1016/j.jtho.2017.10.033
Biomarker‐Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma
A. Tsao (2018)
10.1016/j.jtho.2016.06.021
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage‐Mediated T Cell Suppression
Lysanne A. Lievense (2016)
10.1016/j.anndiagpath.2014.02.005
Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.
A. Tsao (2014)
10.2174/138945009789753200
Molecular targets in malignant pleural mesothelioma treatment.
G. Pasello (2009)
10.3892/or.2015.3771
Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma
T. Hirata (2015)
10.4081/MONALDI.2010.302
Treatment of malignant pleural mesothelioma: current status and future directions.
X. Dhalluin (2010)
10.1016/j.surg.2013.06.004
An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
Laurence J. Belin (2013)
10.1016/j.tips.2011.03.011
Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.
Roberto E. Favoni (2011)
10.3233/DMA-2011-0866
Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
A. Franko (2012)
10.2146/ajhp110281
Malignant pleural mesothelioma.
Sheree E Chen (2012)
10.1016/J.EPSC.2015.09.002
Malignant pleural mesothelioma in a child
Jed Brendan Scharf (2015)
10.35376/10324/16329
EFECTOS SOBRE LAS CÉLULAS PLEURALES MALIGNAS DE LA HIPERTERMIA Y CISPLATINO: SÍNTESIS DE PROTEÍNAS PRO-INFLAMATORIAS Y APOPTOSIS CELULAR
Gregorio Guitián Crespo (2016)
10.1016/j.lungcan.2014.06.018
The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
E. Giroux Leprieur (2014)
Semantic Scholar Logo Some data provided by SemanticScholar